Sienna and VivaZome to Evaluate EXO-NETTM for VivaZome’s Exosome-based Therapeutics
-
VivaZome is developing exosome-based therapies for debilitating and/or life-threatening diseases
-
Initial targeted therapy is for the treatment for Critical Limb Ischaemia (CLI) - 4 million patients worldwide
-
VivaZome will assess Sienna’s proprietary EXO-NETTM exosome capture technology to isolate exosomes that will be developed as a treatment for CLI
Melbourne, Australia, 8 November 2019: Sienna Cancer Diagnostics Ltd (ASX: SDX) (“Sienna” or “the Company”), a medical technology company developing and commercialising innovative In-Vitro Diagnostic (IVD) tests, has entered into an agreement with Melbourne-based VivaZome Therapeutics Pty Ltd (“VivaZome”) to assist in the development of a commercial and scalable purification process for VivaZome’s exosome-based therapies.
For further information please download the attached PDF:
Download this document
